KROS Keros Therapeutics, Inc.

8-K Current Report

Filed: February 26, 2026

Health Care

Pharmaceutical Preparations

Keros Therapeutics, Inc. (KROS) 8-K current report filed with SEC EDGAR on February 26, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 5.02: Departure/Election of Directors or Officers
Item 7.01: Regulation FD Disclosure

AI Filing Analysis
8-K

Item 5.02 · Departure/Election of Directors or Officers

• Dr. Carl Gordon resigned from Board and Compensation Committee effective March 9, 2026; no disagreement with Company cited
• Charles Newton appointed Class III director effective March 9, 2026; joins Compensation and Audit Committees — direct replacement for Gordon

+3 more insights

Item 7.01 · Regulation FD Disclosure

• Director changes announced via press release dated February 26, 2026 — details in accompanying exhibit
• Reg FD disclosure ensures all investors receive board change information simultaneously

Other Keros Therapeutics, Inc. 8-K Filings

8-K Mar 9, 2026

8-K Mar 4, 2026

Get deeper insights on Keros Therapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.